Role of inherited genetic variants in rare blood cancer uncovered
Large-scale genetic analysis has helped researchers uncover the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer.
Abzena launches AbZelect CLD platforms
Abzena launches AbZelect™ platforms for improving cell line development efficiency on the pathway to IND.
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindnessDublin, Ireland, and Tampere, Finland - ERS Genomics Limited (‘ERS’), the CRISPR licensing Company,
The emerging business models for digital therapeutics
This article was originally published at Med Device Online.
Guardtech pledge to support NHS aseptic pharmacy units in 2024 after spike in enquiries
The Haverhill cleanroom construction experts have been inundated with enquiries from the nation’s healthcare heroes in recent months
Supporting a Phase III R&D strategy within the anti-infective space
Client Issue An emerging pharmaceutical company sought to evaluate Phase III development strategies for an anti-infective drug with potential to treat a range of patient populations.
A complimentary Cost-Savings Audit Breathe Technology
Breathe Technology is currently providing a free, cost-savings audit. A friendly, no-obligation and knowledgeable service.
Establishing real-world testing and treatment patterns for EGFR NSCLC patients
Client issue Oncology-focused biotech was looking to establish real-world testing and treatment patterns among EGFR NSCLC patients in US, EU, Japan, and Greater China (mainland, HK, and Taiwan).
Antibiotic use is not the only driver of superbugs
For the first time, researchers have analysed the impact of antibiotic use on the rise of treatment-resistant bacteria over the last 20 years in the UK and Norway. They show that while the increase in drug use has amplified the spread of superbugs, it is not the only driver.
Cancer drug discovery accelerated as hundreds of overlooked targets prioritised
A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.
Rare Disease: 2023 in Review
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings.
How to start your health journey: key health skills for success
Creative Nutritionist writes...Happy New Year everyone! I hope you had a lovely Christmas break.
If you are starting your health journey this January, and you are a bit confused as to what to do- don’t worry! I have you covered.
Prism facilitate sale of Cambridge-based medtech design consultancy
Prism Corporate Broking are pleased to announce that we have facilitated the sale of medtech device design and development consultancy, Springboard Pro Ltd, to leading global healthcare packaging and medical device manufacturers, Sanner GmbH (Sanner Group), a company backed by Europe’s leading healthcare specialist private equity investor, GHO Capital.
Tributes roll in for transplant pioneer Sir Roy
Addenbrooke’s Hospital staff have been paying tribute to pioneering transplant surgeon, Sir Roy Calne, who died over the weekend, aged 93.
Cellular Origins, a TTP Company, establishes Advisory Board of global industry leaders
Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives
Arecor announces expansion of existing specialty hospital formulation collaboration
Cambridge - Arecor Therapeutics, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
Corazon Health has been re-accredited by the Good Business Charter
Corazon Health has been re-accredited by the Good Business Charter in recognition of responsible business practices.
Evolving business models: Pharmaceutical incubators
As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts.
AI in drug discovery and development: Will it live up to the hype?
The recent explosion of generative artificial intelligence (AI) has fueled interest in and concern over the use of AI in drug discovery and research and development.
Versius customer reach increases as CMR Surgical closes 2023 with strongest quarter on record
After a record quarter, CMR closes the year with a Versius global install base more than 50% higher than 2022 Over 17,000 surgical procedures completed using Versius, representing a procedural growth rate of over 60% in 2023, compared with 2022, with an increasing number of compl
Cambridge achievers recognised in 2024 New Year Honours list
Academics and staff associated with the University of Cambridge feature in the 2024 list, which recognises the achievements and service of people across the UK, from all walks of life.
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cambridge, UK — January 2024 — Cuttsy+Cuttsy, a healthcare communication agency, is pleased to announce the appointment of Harriet Karia as its first Managing Director. This move follows a period of substantial growth and is a practical step towards the agency's future plans.
Love Your Liver Awareness Month
Love Your Liver Awareness Month is a campaign run by the British Liver Trust devoted to liver health aiming to put a spotlight on the risk factors of liver disease and the steps people can take to look after their liver.
BioResource-supported study finds ongoing brain injury caused by COVID-19 may not always be detected by routine tests
A new study published in Nature Communications details that markers of brain injury are present in the blood many months after COVID-19 infection, despite inflammation blood tests being normal.